MedTrace Logo

Nitazoxanide in Prevention of Secondary Spontaneous Peritonitis

NCT04746937 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2021-02-10

No results posted yet for this study

Summary

the study is to evaluate the possible efficacy and safety of nitazoxanide as an adjuvant therapy in the secondary prevention of SBP in patient with cirrhosis.

Conditions

  • Spontaneous Bacterial Peritonitis

Interventions

DRUG

Nitazoxanide

nitazoxanide adjuvant to standard therapy

DRUG

Norfloxacin

Standard therapy

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Sahar M. Elhagar, Professor · Supervisor for my master degree

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-31
Primary Completion
2022-03-31
Completion
2022-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04746937 on ClinicalTrials.gov